Abstract
Abstract
Background
There is increasing research focus on prediction and prevention of rheumatoid arthritis (RA). Information about risk of RA is increasingly available via direct-to-consumer testing. However, there is limited understanding of public perceptions around predictive testing for RA. This study explores public perceptions of predictive testing for RA in comparison to breast cancer (BC) and early-onset Alzheimer’s disease (AD).
Methods
Four focus groups with 21 members of the public were conducted using hypothetical vignettes about predictive testing for each disease. Transcripts of focus group proceedings were analysed inductively using thematic analysis.
Results
Thematic analysis of the data produced three key themes: decision-making factors, consequences, and consumer needs. Factors suggested that might influence decision-making about predictive testing included family history, fear, and perceived severity and treatability of the illness. RA was perceived to be less severe and more treatable than BC/AD. Potential consequences of predictive testing across all diseases included lifestyle modification, planning for the future and discrimination by employers or insurers. Predictive testing for RA was perceived to have less potential for negative psychological consequences than other diseases. Participants highlighted that individuals undertaking predictive testing should be signposted to appropriate support services and receive information on the accuracy of predictive testing. It was suggested that strategies to mitigate concerns regarding communication and confidentiality of risk results are required.
Conclusions
The findings of this study reflect public misunderstandings regarding RA that may impact the uptake of and responses to predictive testing, and key informational needs of individuals considering a predictive test. Predictive strategies should be accompanied by awareness-raising initiatives and informational resources.
Funder
Versus Arthritis
Riksbankens Jubileumsfond
NIHR Birmingham Biomedical Research Centre
Publisher
Springer Science and Business Media LLC
Reference33 articles.
1. Majithia V, Geraci SA. Rheumatoid arthritis: diagnosis and management. Am J Med. 2007;120(11):936–9. https://doi.org/10.1016/j.amjmed.2007.04.005.
2. Rindfleisch JA, Muller D. Diagnosis and management of rheumatoid arthritis. Am Fam Phys. 2005;72(6):1037–47.
3. CORDIS. Towards early diagnosis and biomarker validation in arthritis management. https://cordis.europa.eu/project/id/305549.
4. Sparks JA, Iversen MD, Yu Z, Triedman NA, Prado MG, Kroouze RM, et al. Disclosure of personalized rheumatoid arthritis risk using genetics, biomarkers, and lifestyle factors to motivate health behavior improvements: a randomized controlled trial. Arthritis Care Res. 2018;70(6):823–33. https://doi.org/10.1002/acr.23411.
5. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL, et al. Autoantibodies predict progression to rheumatoid arthritis in undifferentiated arthritis: a prospective cohort study. Arthritis Res Ther. 2003;5(Suppl 1):28. https://doi.org/10.1186/ar658.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献